Targeted therapy in gastroesophageal cancers: past, present and future.

Gastroenterol Rep (Oxf) · 2015 · PMC4650980 · PMID 26510453

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The OS showed a trend towards improvement with regorafenib but did not reach significance (25 weeks for the regorafenib vs 19.4 weeks for placebo).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.